Moffitt Cancer Center

Moffitt Cancer Center Launches an Enhanced Form of TIL Therapy Study for NSCLC – ALK Positive

ALK Positive shared a post on LinkedIn:

“For ALK-positive patients who have progressed after targeted therapy, a new clinical trial at Moffitt Cancer Center in Tampa, FL offers renewed hope. This Phase 1 study explores an enhanced form of Tumor-Infiltrating Lymphocyte (TIL) therapy – empowering a patient’s own immune cells with a genetic boost to better recognize and fight cancer.

The trial is open to patients who have:

  • NSCLC driven by ALK, EGFR, ROS1, or HER2 mutations
  • Safely accessible tumor for TIL harvest by surgical resection or excisional biopsy, expected to yield at least 1.5 cm³ of viable tissue
  • Disease progression after standard treatments (including targeted therapies)
  • Ability to undergo surgical tumor resection

For more information, visit here.”

Moffitt Cancer Center

More posts featuring ALK Positive on OncoDaily.

ALK mutations ALK Positive cancer EGFR Mutations HER2 mutations Moffitt Cancer Center NSCLC OncoDaily Oncology ROS1 mutations TIL Therapy Tumor-Infiltrating Lymphocyte (TIL) therapy